The multifaceted von Hippel-Lindau tumour suppressor protein.
about
WSB1: from homeostasis to hypoxiaTargeting Protein-Protein Interactions in the HIF SystemNew and emerging factors in tumorigenesis: an overviewThe unfolded protein response in retinal vascular diseases: implications and therapeutic potential beyond protein foldingThe ever-expanding role of HIF in tumour and stromal biologyThe preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agentChromatin and oxygen sensing in the context of JmjC histone demethylasesDisease pathways at the Rat Genome Database Pathway Portal: genes in context-a network approach to understanding the molecular mechanisms of disease.The von Hippel-Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoformMacrophage Migration Inhibitory Factor Secretion Is Induced by Ionizing Radiation and Oxidative Stress in Cancer Cells.Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary MalignanciesBeluga whale pVHL enhances HIF-2α activity via inducing HIF-2α proteasomal degradation under hypoxiaHypoxia as a therapy for mitochondrial disease.Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2α expression and cell proliferation.Tumour and patient factors in renal cell carcinoma-towards personalized therapy.Rethinking pheochromocytomas and paragangliomas from a genomic perspective.Intrinsic gene changes determine the successful establishment of stable renal cancer cell lines from tumor tissue.NETs: organ-related epigenetic derangements and potential clinical applications.Overexpression of HOXC11 homeobox gene in clear cell renal cell carcinoma induces cellular proliferation and is associated with poor prognosis.Profiling of the metabolic transcriptome via single molecule molecular inversion probes.Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.KDM2 Family Members are Regulated by HIF-1 in HypoxiaHomo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles.Quantitative proteomics to study a small molecule targeting the loss of von Hippel-Lindau in renal cell carcinomas.The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma.Consequences of VHL Loss on Global DNA Methylome.The HIF and other quandaries in VHL disease.A Late G1 Lipid Checkpoint That Is Dysregulated in Clear Cell Renal Carcinoma Cells.Metastatic phaeochromocytoma in a 23-year-old woman with an unclassified variant in the von Hippel Lindau disease gene: how can the pathogenicity of this variant be determined?Hypoxia and Chromatin: A Focus on Transcriptional Repression Mechanisms.HIF-2α-pVHL complex reveals broad genotype-phenotype correlations in HIF-2α-driven disease
P2860
Q26740274-165A1E32-E47B-490E-8EE6-1FB2F0D59EBAQ26753176-1677B481-3EE2-4EB8-A197-276BA98B6BEFQ26801253-EC404C3C-870B-4B2C-9AB9-F60CB6F32378Q26852080-06A253A4-0628-4250-BE2A-D46BEAADA53FQ28079015-69BD5061-C97B-4F78-96EC-1383B613DF66Q33728258-3288D2E8-3466-4ACF-9422-8DC969CD8D5AQ34103385-65443904-7D0E-4BFA-AA3D-094E2D4F379CQ34312452-94F469C2-7409-4728-B97B-598B7466B598Q35863138-9BF446D1-562B-4C66-9ABF-3B6E886F22D5Q35888073-13964103-65D0-4947-A7F3-3E83B64C1A98Q35891379-45ED2E5D-D96B-45E6-AA4B-521AA4B5B337Q35897966-E8662F18-A31D-4AA5-825E-46DC6647D698Q36274373-702CEBDE-C613-44E9-800A-4A2CFDD23F72Q36882394-A1F83307-B23E-4249-BC54-676BB4F60A43Q37093230-E24B5AA6-6D95-4D7B-ADBC-7DA7709157FAQ38418649-A9D38FD6-43A7-42E3-80EC-E071ED7F26DAQ38509463-13C501D6-1360-4FE3-80B4-FA67E82729A3Q38714028-5ED088A3-C2B5-48E4-975E-E5A6A67DCA88Q38841735-DFE2B377-33A7-4683-A340-81FC25FAE6E8Q38932099-7DF25E47-243D-4476-8762-C6D1AC5222CEQ41198110-1CAD628E-9763-4DEB-96D5-E1B8CAA5A9E1Q41574276-F779DE45-D23B-401E-AE35-1EB240BCEE5CQ42074689-50BB907F-DE9B-4339-937C-11FA1E82C68CQ42217007-F3A779BD-6736-42DC-B5CF-FA797D8B6378Q46219895-6ECB9D4F-4E44-4EF3-AB3C-EE1679C40BAAQ48169059-F0301BF3-2D52-456D-A7CD-402CE7E26E99Q48295398-93102F22-C187-4DD3-91D9-7E45DAB939BDQ49405081-A8A37770-494A-4090-BE80-E116FCD90BF8Q49789775-99D038E7-4A1A-416B-9624-2C4006C7A74DQ50026055-DA69140F-F0C4-4B40-BF4F-4B1252C3D3C0Q51271668-5DDA1DFE-EE4A-45E7-8F34-9A69834982F6Q53653503-05056F90-4402-4D06-A075-ECD56ACF317EQ55689936-5308E181-6B08-47CE-AA89-ECB683622114Q58721805-CC472472-9DF1-4174-B234-3CCF192FD2B2
P2860
The multifaceted von Hippel-Lindau tumour suppressor protein.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The multifaceted von Hippel-Lindau tumour suppressor protein.
@en
The multifaceted von Hippel-Lindau tumour suppressor protein.
@nl
type
label
The multifaceted von Hippel-Lindau tumour suppressor protein.
@en
The multifaceted von Hippel-Lindau tumour suppressor protein.
@nl
prefLabel
The multifaceted von Hippel-Lindau tumour suppressor protein.
@en
The multifaceted von Hippel-Lindau tumour suppressor protein.
@nl
P2860
P1433
P1476
The multifaceted von Hippel-Lindau tumour suppressor protein.
@en
P2093
Claire M Robinson
Michael Ohh
P2860
P304
P356
10.1016/J.FEBSLET.2014.02.026
P407
P577
2014-02-25T00:00:00Z